Betamethasone Dipropionate; Calcipotriene Patent Expiration
Betamethasone Dipropionate; Calcipotriene is used for treating schizophrenia, bipolar disorder, and major depressive disorder. It was first introduced by Leo Pharma As
Betamethasone Dipropionate; Calcipotriene Patents
Given below is the list of patents protecting Betamethasone Dipropionate; Calcipotriene, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Enstilar | US10130640 | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid | Jun 10, 2031 | Leo Pharma As |
| Enstilar |
US10130640 (Pediatric) | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid | Dec 10, 2031 | Leo Pharma As |
| Enstilar | US10617698 | Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid | Jun 10, 2031 | Leo Pharma As |
| Enstilar | US10660908 | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid | Jun 10, 2031 | Leo Pharma As |
| Enstilar | US10682364 | Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid | Jun 10, 2031 | Leo Pharma As |
| Enstilar | US10688108 | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid | Jun 10, 2031 | Leo Pharma As |
| Enstilar | US10716799 | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid | Jun 10, 2031 | Leo Pharma As |
| Enstilar | US6753013 | Pharmaceutical composition |
Jan 27, 2020
(Expired) | Leo Pharma As |
| Enstilar | US9119781 | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid | Jun 10, 2031 | Leo Pharma As |
| Enstilar |
US9119781 (Pediatric) | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid | Dec 10, 2031 | Leo Pharma As |
| Enstilar | US9566286 | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid | Jun 10, 2031 | Leo Pharma As |
| Taclonex | US5763426 | Crystalline form of a vitamin D analogue |
Jun 09, 2015
(Expired) | Leo Pharma As |
| Taclonex | US6753013 | Pharmaceutical composition |
Jan 27, 2020
(Expired) | Leo Pharma As |
| Taclonex | US6787529 | Topical composition |
Jan 27, 2020
(Expired) | Leo Pharma As |
| Taclonex | USRE39706 | Crystalline form of a vitamin D analogue |
Jun 09, 2015
(Expired) | Leo Pharma As |
| Wynzora | US10265265 | Topical composition | Sep 27, 2027 | Mc2 |
| Wynzora | US11638711 | NULL | Mar 18, 2039 | Mc2 |
| Wynzora | US11696919 | Topical composition | Mar 18, 2039 | Mc2 |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Betamethasone Dipropionate; Calcipotriene's patents.
Latest Legal Activities on Betamethasone Dipropionate; Calcipotriene's Patents
Given below is the list recent legal activities going on the following patents of Betamethasone Dipropionate; Calcipotriene.
| Event | Date | Patent/Publication |
|---|---|---|
 | ||
| Patent eCofC Notification | 19 Mar, 2024 | US11696919 |
| Mail Patent eCofC Notification | 19 Mar, 2024 | US11638711 |
| Mail Patent eCofC Notification | 19 Mar, 2024 | US11696919 |
| Patent eCofC Notification | 19 Mar, 2024 | US11638711 |
| Email Notification | 19 Mar, 2024 | US11696919 |
| Recordation of Patent eCertificate of Correction | 19 Mar, 2024 | US11696919 |
| Email Notification | 19 Mar, 2024 | US11638711 |
| Recordation of Patent eCertificate of Correction | 19 Mar, 2024 | US11638711 |
| Mail Certificate of Correction Memo | 28 Feb, 2024 | US11696919 |
| Mail Certificate of Correction Memo | 28 Feb, 2024 | US11638711 |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Betamethasone Dipropionate; Calcipotriene Generics
Several generic applications have been filed for Betamethasone Dipropionate; Calcipotriene. The first generic version for Betamethasone Dipropionate; Calcipotriene was by Chartwell Rx Sciences Llc and was approved on Jan 14, 2013. And the latest generic version is by Glenmark Pharmaceuticals Ltd and was approved on Mar 21, 2023.
Given below is the list of companies who have filed for Betamethasone Dipropionate; Calcipotriene generic.
1. TARO
Taro Pharmaceuticals Inc has filed for 1 generic for Betamethasone Dipropionate; Calcipotriene. This 0.064%;0.005% version comes by the name CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE. Given below are the details of the strengths of this generic introduced by Taro.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.064%; 0.005% | suspension | Prescription | TOPICAL | AB | Sep 2, 2020 |
2. CHARTWELL RX
Chartwell Rx Sciences Llc has filed for 1 generic for Betamethasone Dipropionate; Calcipotriene. This 0.064%;0.005% version comes by the name CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE. Given below are the details of the strengths of this generic introduced by Chartwell Rx.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.064%; 0.005% | ointment | Discontinued | TOPICAL | N/A | Jan 14, 2013 |
3. COSETTE
Cosette Pharmaceuticals Inc has filed for 1 generic for Betamethasone Dipropionate; Calcipotriene. This 0.064%;0.005% version comes by the name CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE. Given below are the details of the strengths of this generic introduced by Cosette.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.064%; 0.005% | suspension | Prescription | TOPICAL | AB | May 11, 2020 |
4. GLENMARK PHARMS LTD
Glenmark Pharmaceuticals Ltd has filed for 1 generic for Betamethasone Dipropionate; Calcipotriene. This 0.064%;0.005% version comes by the name CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE. Given below are the details of the strengths of this generic introduced by Glenmark Pharms Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.064%; 0.005% | aerosol, foam | Prescription | TOPICAL | AB | Mar 21, 2023 |
5. PADAGIS ISRAEL
Padagis Israel Pharmaceuticals Ltd has filed for 1 generic for Betamethasone Dipropionate; Calcipotriene. This 0.064%;0.005% version comes by the name CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE. Given below are the details of the strengths of this generic introduced by Padagis Israel.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.064%; 0.005% | suspension | Prescription | TOPICAL | AB | Sep 11, 2020 |